This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

intrauterine contraceptive (progestogen) and breast cancer risk

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A Danish study (78,595 new users; 78,595 nonusers) found link between levonorgestrel-releasing intrauterine systems (LNG-IUSs) & increased breast cancer risk in females aged 15-49 years, vs nonuse (HR 1.4; 95% CI, 1.2-1.5) (1)

  • the absolute risk low but there was excess risk of 14/10 000
  • the risk did not increase with duration of use

The Danish study evidence contrasts with the results from a systematic review and meta-analysis by Heting et al (2):

  • results suggested that LNG-IUS was not a risk factor for breast cancer
  • the study authors note though that:
    • since there were six articles that were not included in the meta-analysis and their data were not used, we should be cautious about this conclusion

Reference:

  1. Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. Published online October 16, 2024.
  2. Heting M et al. Levonorgestrel intrauterine system and breast cancer risk: An updated systematic review and meta-analysis of observational studies. Heliyon. 2023 Mar 22;9(4):e14733.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.